Seres Therapeutics, Inc. (MCRB)

Every figure this model derived for MCRB, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 37,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 15,594,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 42,348,000 AssetsCurrent 2026-06-30
current liabilities 20,031,000 LiabilitiesCurrent 2026-06-30
equity 34,534,000 StockholdersEquity 2026-06-30
interest expense 0 InterestPaidNet 2025-12-31
ocf -51,258,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 1,883,000 Revenues 2026-06-30
sbc 9,186,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up MCRB on one particular measure came for.

RatioValue
current ratio2.11
current ratio reported2.11
deferred revenue growth278.99
dilution pct14.17
growth cv5.0
roic-350.51
sbc pct revenue487.84

What to be careful about

What this model itself distrusts about MCRB's figures. Written by the derivation as it ran, not added afterwards.